Imunon, INC

Imunon, Inc. reported third quarter 2026 financial results, detailing progress in its Phase 3 OVATION 3 study for IMNN-001 and strategic corporate developments.

Imunon, Inc. has made an investor presentation available for use in upcoming investor calls and conferences.

Imunon, Inc. has entered into an agreement to sell its ThermoDox assets to VoxelDox Therapeutics, Inc., receiving equity, milestone payments, and royalties contingent on VoxelDox's financing and development success.

Imunon, Inc. has entered into an Exchange Agreement to convert $1.2 million of its A-1 Note principal into Series B Preferred Stock, impacting its capital structure.

Imunon, Inc. announces compensatory programs allowing executive officers to receive a portion of their base salary in company stock, with additional stock grants.

Imunon, Inc. announced its second quarter 2026 financial results, highlighting strong enrollment in its Phase 3 OVATION 3 study for IMNN-001 and positive preliminary data from a minimal residual disease study.

Imunon, Inc. reports continued clinical development for its lead candidate IMNN-001, but faces substantial doubt regarding its ability to continue as a going concern due to significant operating losses and limited cash reserves.

Imunon, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development and significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Imunon, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $4.2 million and continued progress in its Phase 3 OVATION 3 ovarian cancer trial.

Imunon, Inc. reported a reduced net loss for the nine months ended September 30, 2025, while advancing its lead ovarian cancer immunotherapy into Phase 3 and presenting positive Phase 2 data, despite ongoing going concern doubts.

Imunon reported a reduced net loss and positive clinical data for its lead ovarian cancer immunotherapy, IMNN-001, while addressing significant going concern and Nasdaq listing challenges.

Imunon, Inc. announces its financial results for the first quarter of 2025, highlighting advancements in its IMNN-001 ovarian cancer treatment and IMNN-101 COVID-19 vaccine programs, while also acknowledging substantial doubt about its ability to continue as a going concern.

Imunon, Inc. announced positive final Phase 2 data for its lead ovarian cancer immunotherapy, IMNN-001, showing significant overall survival benefits, but also disclosed substantial doubt about its ability to continue as a going concern.

Imunon's 10-K filing highlights the company's continued losses, its focus on the IMNN-001 ovarian cancer immunotherapy program, and its next-generation vaccine initiative.

Imunon Inc.'s 10-K filing details the company's financial status, ongoing clinical trials, and advancements in its immunotherapy and vaccine platforms.

Donald P Braun, a Director of Imunon, Inc., received 11,746 shares of common stock on November 6, 2026.

James E Dentzer, a Director of Imunon, Inc., received 13,166 shares of common stock on November 6, 2026.

Christine A Pellizzari, a Director of Imunon, Inc., received 13,166 shares of common stock on November 6, 2026.

Frederick J. Fritz, a Director of Imunon, Inc., received 13 shares of common stock on November 6, 2026.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 1,596 shares of common stock on November 6, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 3,804 shares of common stock on November 6, 2026.

Imunon, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026, to elect directors, ratify auditors, and vote on executive compensation and stock incentive plan amendments.

IMUNON, INC. is calling for its annual stockholder meeting on July 11, 2025, to vote on critical proposals including a reverse stock split, a significant increase in authorized shares, and the approval of shares underlying recent warrants, all aimed at addressing Nasdaq listing deficiencies and securing future funding.

Imunon, Inc. will hold its annual stockholders meeting virtually on June 12, 2024, to elect directors, ratify the selection of its accounting firm, and conduct an advisory vote on executive compensation.

Imunon, Inc. has entered into an Asset Purchase Agreement to sell its ThermoDox program assets to VoxelDox Therapeutics, Inc., a move aimed at streamlining operations and focusing on its core DNA-based immunotherapy pipeline.

Imunon, a clinical-stage biotechnology company, is registering shares for resale by existing investors following a private placement, while simultaneously grappling with severe financial challenges, including multiple Nasdaq delisting notices and substantial doubt about its ability to continue as a going concern.

Imunon, Inc. is proceeding with a public offering of common stock and warrants, aiming to raise capital for general corporate purposes, including clinical development.

Imunon, Inc. plans to raise capital through a public offering of up to 15,000,000 shares of common stock and accompanying warrants, aiming to generate approximately $12 million for general corporate purposes.

Imunon, a clinical-stage biotech, aims to raise capital through a public offering of common stock, pre-funded warrants, and common warrants.

Imunon, Inc. has filed an amendment to its Form S-1 registration statement to allow selling stockholders to resell up to 5,000,000 shares of common stock issuable upon the exercise of outstanding warrants.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 450,315 shares, representing 9.99% of Imunon, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 396,718 shares, representing 9.99% of Imunon, Inc.'s common stock, as of March 31, 2026.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri report a combined 0.01% beneficial ownership in Imunon, Inc. common stock.

Intracoastal Capital LLC and its principals have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Imunon, Inc. as of June 30, 2025.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a passive beneficial ownership of 5.5% in Imunon, Inc. common stock.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly disclosed a 7.9% beneficial ownership stake in Imunon, Inc., primarily through warrants.